Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

India’s economy is navigating a phase of subdued demand as growth in key sectors slows down. Multiple dynamics impact exports ...

Sagar Doshi of Nuvama Professional Clients Group recommends these three stocks today- Oil and Natural Gas Corporation Ltd ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

The report said "Nifty EPS is likely to grow 2 per cent (versus 4 per cent in H1FY25)-posing downgrade risks to H2FY25 consensus estimate of mid-teens growth".

Multi-Manager ICVC also sold 4.35 lakh shares or 0.52 percent stake in Dr Lal PathLabs at Rs 2,997.11 per share.

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...